Cargando…

Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can)

OBJECTIVE: To investigate the association between total serum cholesterol (TSC) and cancer incidence in the Metabolic syndrome and Cancer project (Me-Can). METHODS: Me-Can consists of seven cohorts from Norway, Austria, and Sweden including 289,273 male and 288,057 female participants prospectively...

Descripción completa

Detalles Bibliográficos
Autores principales: Strohmaier, Susanne, Edlinger, Michael, Manjer, Jonas, Stocks, Tanja, Bjørge, Tone, Borena, Wegene, Häggström, Christel, Engeland, Anders, Nagel, Gabriele, Almquist, Martin, Selmer, Randi, Tretli, Steinar, Concin, Hans, Hallmans, Göran, Jonsson, Håkan, Stattin, Pär, Ulmer, Hanno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553083/
https://www.ncbi.nlm.nih.gov/pubmed/23372693
http://dx.doi.org/10.1371/journal.pone.0054242
_version_ 1782256780414287872
author Strohmaier, Susanne
Edlinger, Michael
Manjer, Jonas
Stocks, Tanja
Bjørge, Tone
Borena, Wegene
Häggström, Christel
Engeland, Anders
Nagel, Gabriele
Almquist, Martin
Selmer, Randi
Tretli, Steinar
Concin, Hans
Hallmans, Göran
Jonsson, Håkan
Stattin, Pär
Ulmer, Hanno
author_facet Strohmaier, Susanne
Edlinger, Michael
Manjer, Jonas
Stocks, Tanja
Bjørge, Tone
Borena, Wegene
Häggström, Christel
Engeland, Anders
Nagel, Gabriele
Almquist, Martin
Selmer, Randi
Tretli, Steinar
Concin, Hans
Hallmans, Göran
Jonsson, Håkan
Stattin, Pär
Ulmer, Hanno
author_sort Strohmaier, Susanne
collection PubMed
description OBJECTIVE: To investigate the association between total serum cholesterol (TSC) and cancer incidence in the Metabolic syndrome and Cancer project (Me-Can). METHODS: Me-Can consists of seven cohorts from Norway, Austria, and Sweden including 289,273 male and 288,057 female participants prospectively followed up for cancer incidence (n = 38,978) with a mean follow-up of 11.7 years. Cox regression models with age as the underlying time metric were used to estimate hazard ratios (HR) and their 95% confidence intervals (CI) for quintiles of cholesterol levels and per 1 mmol/l, adjusting for age at first measurement, body mass index (BMI), and smoking status. Estimates were corrected for regression dilution bias. Furthermore, we performed lag time analyses, excluding different times of follow-up, in order to check for reverse causation. RESULTS: In men, compared with the 1st quintile, TSC concentrations in the 5th quintile were borderline significantly associated with decreasing risk of total cancer (HR = 0.94; 95%CI: 0.88, 1.00). Significant inverse associations were observed for cancers of the liver/intrahepatic bile duct (HR = 0.14; 95%CI: 0.07, 0.29), pancreas cancer (HR = 0.52, 95% CI: 0.33, 0.81), non-melanoma of skin (HR = 0.67; 95%CI: 0.46, 0.95), and cancers of the lymph−/hematopoietic tissue (HR = 0.68, 95%CI: 0.54, 0.87). In women, hazard ratios for the 5th quintile were associated with decreasing risk of total cancer (HR = 0.86, 95%CI: 0.79, 0.93) and for cancers of the gallbladder (HR = 0.23, 95%CI: 0.08, 0.62), breast (HR = 0.70, 95%CI: 0.61, 0.81), melanoma of skin (HR = 0.61, 95%CI: 0.42, 0.88), and cancers of the lymph−/hematopoietic tissue (HR = 0.61, 95%CI: 0.44, 0.83). CONCLUSION: TSC was negatively associated with risk of cancer overall in females and risk of cancer at several sites in both males and females. In lag time analyses some associations persisted, suggesting that for these cancer sites reverse causation did not apply.
format Online
Article
Text
id pubmed-3553083
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35530832013-01-31 Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can) Strohmaier, Susanne Edlinger, Michael Manjer, Jonas Stocks, Tanja Bjørge, Tone Borena, Wegene Häggström, Christel Engeland, Anders Nagel, Gabriele Almquist, Martin Selmer, Randi Tretli, Steinar Concin, Hans Hallmans, Göran Jonsson, Håkan Stattin, Pär Ulmer, Hanno PLoS One Research Article OBJECTIVE: To investigate the association between total serum cholesterol (TSC) and cancer incidence in the Metabolic syndrome and Cancer project (Me-Can). METHODS: Me-Can consists of seven cohorts from Norway, Austria, and Sweden including 289,273 male and 288,057 female participants prospectively followed up for cancer incidence (n = 38,978) with a mean follow-up of 11.7 years. Cox regression models with age as the underlying time metric were used to estimate hazard ratios (HR) and their 95% confidence intervals (CI) for quintiles of cholesterol levels and per 1 mmol/l, adjusting for age at first measurement, body mass index (BMI), and smoking status. Estimates were corrected for regression dilution bias. Furthermore, we performed lag time analyses, excluding different times of follow-up, in order to check for reverse causation. RESULTS: In men, compared with the 1st quintile, TSC concentrations in the 5th quintile were borderline significantly associated with decreasing risk of total cancer (HR = 0.94; 95%CI: 0.88, 1.00). Significant inverse associations were observed for cancers of the liver/intrahepatic bile duct (HR = 0.14; 95%CI: 0.07, 0.29), pancreas cancer (HR = 0.52, 95% CI: 0.33, 0.81), non-melanoma of skin (HR = 0.67; 95%CI: 0.46, 0.95), and cancers of the lymph−/hematopoietic tissue (HR = 0.68, 95%CI: 0.54, 0.87). In women, hazard ratios for the 5th quintile were associated with decreasing risk of total cancer (HR = 0.86, 95%CI: 0.79, 0.93) and for cancers of the gallbladder (HR = 0.23, 95%CI: 0.08, 0.62), breast (HR = 0.70, 95%CI: 0.61, 0.81), melanoma of skin (HR = 0.61, 95%CI: 0.42, 0.88), and cancers of the lymph−/hematopoietic tissue (HR = 0.61, 95%CI: 0.44, 0.83). CONCLUSION: TSC was negatively associated with risk of cancer overall in females and risk of cancer at several sites in both males and females. In lag time analyses some associations persisted, suggesting that for these cancer sites reverse causation did not apply. Public Library of Science 2013-01-23 /pmc/articles/PMC3553083/ /pubmed/23372693 http://dx.doi.org/10.1371/journal.pone.0054242 Text en © 2013 Strohmaier et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Strohmaier, Susanne
Edlinger, Michael
Manjer, Jonas
Stocks, Tanja
Bjørge, Tone
Borena, Wegene
Häggström, Christel
Engeland, Anders
Nagel, Gabriele
Almquist, Martin
Selmer, Randi
Tretli, Steinar
Concin, Hans
Hallmans, Göran
Jonsson, Håkan
Stattin, Pär
Ulmer, Hanno
Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can)
title Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can)
title_full Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can)
title_fullStr Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can)
title_full_unstemmed Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can)
title_short Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can)
title_sort total serum cholesterol and cancer incidence in the metabolic syndrome and cancer project (me-can)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553083/
https://www.ncbi.nlm.nih.gov/pubmed/23372693
http://dx.doi.org/10.1371/journal.pone.0054242
work_keys_str_mv AT strohmaiersusanne totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan
AT edlingermichael totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan
AT manjerjonas totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan
AT stockstanja totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan
AT bjørgetone totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan
AT borenawegene totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan
AT haggstromchristel totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan
AT engelandanders totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan
AT nagelgabriele totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan
AT almquistmartin totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan
AT selmerrandi totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan
AT tretlisteinar totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan
AT concinhans totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan
AT hallmansgoran totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan
AT jonssonhakan totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan
AT stattinpar totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan
AT ulmerhanno totalserumcholesterolandcancerincidenceinthemetabolicsyndromeandcancerprojectmecan